AIDS-Related Cancers: Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

HIV infection dramatically increases cancer risk through three overlapping mechanisms: profound cellular immunodeficiency (depleted CD4 T-cells allowing uncontrolled oncogenic viral replication), chronic immune activation and systemic inflammation, and co-infection with oncogenic viruses that exploit immune suppression. The three AIDS-defining cancers — Kaposi sarcoma (KS), primary CNS lymphoma (PCNSL), and invasive cervical carcinoma — are diagnostic criteria for AIDS stage disease when they occur in HIV-positive individuals, typically at CD4 counts below 200 cells/μL. Non-AIDS-defining cancers significantly elevated in people living with HIV include anal cancer (40-fold increased risk), Hodgkin lymphoma (8-10x), hepatocellular carcinoma (5-7x from HBV/HCV co-infection), lung cancer (3-4x, compounded by high smoking prevalence), and oropharyngeal cancer (HPV-driven). Before the availability of combination antiretroviral therapy (ART) in 1996, AIDS-defining cancers were leading causes of death in HIV-positive individuals. Since widespread ART adoption, rates of AIDS-defining cancers have declined by over 70%; however, the burden of non-AIDS-defining cancers has increased as HIV-positive patients live longer. Cancer is now the leading cause of non-AIDS death in people living with HIV in high-income countries.

Each AIDS-related cancer has a distinct oncogenic mechanism reflecting the specific oncovirus or co-carcinogen involved. Kaposi sarcoma: caused exclusively by Kaposi sarcoma-associated herpesvirus (KSHV, also known as HHV-8), an oncogenic herpesvirus that infects vascular endothelial cells and establishes latency. Risk is concentrated in men who have sex with men (MSM) in whom HHV-8 seroprevalence approaches 50%; HHV-8 seroprevalence is over 50% in sub-Saharan Africa (endemic KS). Primary CNS lymphoma: caused by Epstein-Barr virus (EBV) transforming immunoblasts in the immunosuppressed CNS — occurs almost exclusively when CD4 counts fall below 50 cells/μL, representing severe immunodeficiency. Invasive cervical cancer: persistent infection with high-risk HPV subtypes (16, 18, 31, 33) in HIV-positive women, who have higher HPV infection rates, higher-risk HPV type distribution, and profoundly impaired immune clearance of HPV-infected cells. Non-AIDS-defining cancers — anal SCC (HPV 16/18), Hodgkin lymphoma (EBV), hepatocellular carcinoma (HBV/HCV), and lung cancer (tobacco) — reflect specific oncoviral or carcinogen interactions potentiated by residual immune dysfunction. Additional cancer risk factors in HIV-positive populations: high smoking prevalence (2-3x general population), heavy alcohol use, hepatitis B and C co-infection, and use of immunosuppressive antiretroviral medications in the early ART era.

Clinical presentation varies markedly by cancer type. Kaposi sarcoma: painless violaceous (purple-red-brown), flat or raised skin lesions that do not blanch with pressure, most commonly on the face, lower extremities, oral cavity (hard palate and gingiva), and genitalia; GI tract KS causes occult GI bleeding, diarrhea, abdominal pain, and protein-losing enteropathy; pulmonary KS causes progressive dyspnea, cough, and hemoptysis mimicking Pneumocystis pneumonia. Primary CNS lymphoma: focal neurological deficits (hemiparesis, aphasia, ataxia) developing subacutely over weeks; cognitive decline and behavioral changes from frontal lobe involvement; seizures; and signs of raised intracranial pressure (headache, nausea, papilledema). Invasive cervical cancer: postcoital or intermenstrual vaginal bleeding; abnormal vaginal discharge (often blood-tinged or malodorous); pelvic pain in locally advanced disease; leg edema or urinary symptoms from parametrial extension. General HIV-related constitutional symptoms: unexplained fever, drenching night sweats, weight loss exceeding 10% (B symptoms) — which may indicate lymphoma, KS, or opportunistic malignancy — in any HIV-positive patient regardless of CD4 count. Lymphoma in HIV: rapidly enlarging lymph node masses, hepatosplenomegaly, and B symptoms with high LDH.

HIV status and immune assessment are fundamental: CD4 cell count, HIV RNA viral load, and current ART regimen guide cancer risk, treatment eligibility, and drug-interaction management. Kaposi sarcoma: clinical diagnosis in typical lesions; punch biopsy of skin or mucosal lesion confirms KS histologically (spindle cell proliferation with slits containing red cells and HHV-8 immunostaining); CT thorax-abdomen-pelvis and endoscopy for GI and pulmonary staging. Primary CNS lymphoma: brain MRI with gadolinium (ring-enhancing or homogeneously enhancing periventricular lesions); CSF EBV PCR (highly specific for PCNSL in HIV — sensitivity approximately 80-90% at CD4 below 50); brain biopsy (stereotactic) for histological confirmation if CSF EBV negative; toxoplasma serology and empiric anti-toxoplasma therapy trial to distinguish from CNS toxoplasmosis. Cervical cancer: cervical Pap smear and HPV co-testing; colposcopy with directed biopsies for CIN2+ or abnormal cytology; FIGO 2018 clinical staging with MRI pelvis for local extent; CT/PET for nodal and distant staging. HIV-associated lymphoma: CT-PET or CT chest-abdomen-pelvis; bone marrow biopsy; CSF cytology (CNS staging); IHC panel; and EBV testing on tumor tissue.

Antiretroviral therapy (ART) is the foundation of all AIDS-related cancer management — immediate or early ART initiation restores CD4 immunity, suppresses HIV viral load, and directly reduces HHV-8, EBV, and HPV oncogenesis. For KS, ART alone induces regression of limited skin disease in immune-reconstituted patients. Kaposi sarcoma: limited cutaneous disease — ART initiation; local therapies (alitretinoin gel, intralesional vinblastine, cryotherapy, radiation); systemic KS — pegylated liposomal doxorubicin (PLD) 20 mg/m2 every 3 weeks is first-line for advanced KS (ORR approximately 45-60%); paclitaxel as second-line. Primary CNS lymphoma: high-dose methotrexate (HD-MTX, 3-8 g/m2 IV) plus ART; rituximab addition is standard for CD20-positive DLBCL; consolidation with whole-brain radiotherapy or autologous SCT in eligible patients; prognosis remains poor (median OS approximately 12-18 months with treatment). Invasive cervical cancer: early stages (IB-IIA) — radical hysterectomy plus pelvic lymphadenectomy or concurrent chemoradiation with cisplatin plus pelvic EBRT (equivalent outcomes); locally advanced (IIB-IVA): concurrent cisplatin-based chemoradiation plus brachytherapy boost; pembrolizumab plus chemotherapy/bevacizumab (KEYNOTE-826) for recurrent/metastatic disease. HIV-associated lymphoma: DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin plus rituximab) is standard for DLBCL in HIV — outcomes approaching HIV-negative patients with CD4 above 200; CNS prophylaxis required. Drug-drug interactions: cobicistat-boosted PI regimens significantly increase taxane, anthracycline, and vinca alkaloid exposure — NNRTI or INI-based ART preferred during chemotherapy.

The prognosis for AIDS-related cancers has been dramatically transformed since the introduction of combination antiretroviral therapy (ART) in 1996, with rates of AIDS-defining cancers declining by over 70%. Kaposi sarcoma limited to the skin in an HIV-positive patient on effective ART has an excellent prognosis — the majority achieve complete or near-complete response with ART alone or with pegylated liposomal doxorubicin; 5-year survival exceeds 70-80% for limited cutaneous KS in ART-adherent patients. Advanced visceral KS (pulmonary, gastrointestinal) carries significantly worse prognosis with median survival of approximately 12-24 months. Primary CNS lymphoma remains the most lethal AIDS-defining malignancy — despite high-dose methotrexate plus ART, median overall survival is approximately 12-18 months; without treatment, survival is measured in weeks. Invasive cervical cancer treated with concurrent chemoradiation achieves 5-year survival of approximately 60-70% for early-stage disease in HIV-positive women maintained on ART, comparable to HIV-negative outcomes. HIV-associated DLBCL treated with DA-EPOCH-R plus ART achieves 5-year survival of approximately 50-60% for patients with CD4 above 200 cells/μL. Factors most strongly associated with better prognosis include: sustained viral suppression on ART, preserved CD4 count above 200-350 cells/μL, early cancer stage at diagnosis, good performance status, and absence of concurrent opportunistic infections. Non-AIDS-defining cancers (lung, anal, liver, oropharyngeal) in people with HIV remain elevated in incidence and benefit from targeted cancer screening programs and prompt specialist management.

Prompt initiation and lifelong adherence to antiretroviral therapy (ART) is the most important preventive strategy, maintaining immune competence (CD4 >500 cells/μL) and suppressing HIV viral load to undetectable levels. HPV vaccination (9-valent Gardasil) is recommended for all HIV-positive individuals up to age 26 (and through 45 in shared decision-making) to prevent cervical, anal, and oropharyngeal cancers. Regular cervical cancer screening (Pap smear + HPV co-testing every 1-3 years) is essential for HIV-positive women. Annual anal cytology and high-resolution anoscopy are recommended for high-risk HIV-positive individuals (MSM, prior anal dysplasia). Smoking cessation is critical, as smoking is the leading contributor to elevated lung cancer risk in HIV. HBV and HCV co-infection treatment reduces liver cancer risk.

HIV-positive individuals who develop any new skin lesion — particularly painless purple, red, or brownish skin or mucosal lesions — should be evaluated promptly for Kaposi sarcoma. New neurological symptoms including progressive headache, cognitive decline, personality changes, or focal weakness require urgent brain imaging to exclude primary CNS lymphoma. Unexplained fever, drenching night sweats, and weight loss (B symptoms) in any person living with HIV require evaluation for lymphoma or opportunistic malignancy. HIV-positive women should not defer cervical cancer screening. Any HIV-positive individual with a CD4 count declining despite ART, or presenting with a new mass, lymph node enlargement, or unexplained constitutional symptoms, requires prompt oncological evaluation — early detection enables curative treatment in many cases.